Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Cited In for PubMed (Select 15537905)

1.

Down-regulation of human enteric antimicrobial peptides by NOD2 during differentiation of the paneth cell lineage.

Tan G, Li RH, Li C, Wu F, Zhao XM, Ma JY, Lei S, Zhang WD, Zhi FC.

Sci Rep. 2015 Feb 11;5:8383. doi: 10.1038/srep08383.

2.

Bifidobacterium infantis attenuates colitis by regulating T cell subset responses.

Zuo L, Yuan KT, Yu L, Meng QH, Chung PC, Yang DH.

World J Gastroenterol. 2014 Dec 28;20(48):18316-29. doi: 10.3748/wjg.v20.i48.18316.

3.

Dendritic cell CD83 homotypic interactions regulate inflammation and promote mucosal homeostasis.

Bates JM, Flanagan K, Mo L, Ota N, Ding J, Ho S, Liu S, Roose-Girma M, Warming S, Diehl L.

Mucosal Immunol. 2015 Mar;8(2):414-28. doi: 10.1038/mi.2014.79. Epub 2014 Sep 10.

4.

TIR-domain-containing adapter-inducing interferon-β (TRIF) regulates Th17-mediated intestinal immunopathology in colitis.

Kanagavelu S, Flores C, Termini JM, Riveron R, Romero L, Chung K, Ruiz J, Hyun J, Yuan X, Dagvadorj J, Fukata M.

Mucosal Immunol. 2015 Mar;8(2):296-306. doi: 10.1038/mi.2014.67. Epub 2014 Jul 30.

5.

Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.

Tuskey A, Behm BW.

Clin Exp Gastroenterol. 2014 May 23;7:173-9. doi: 10.2147/CEG.S39518. eCollection 2014. Review.

6.

Interleukin 23 in Crohn's disease.

Eken A, Singh AK, Oukka M.

Inflamm Bowel Dis. 2014 Mar;20(3):587-95. doi: 10.1097/01.MIB.0000442014.52661.20. Review.

7.

Local and systemic immune mechanisms underlying the anti-colitis effects of the dairy bacterium Lactobacillus delbrueckii.

Santos Rocha C, Gomes-Santos AC, Garcias Moreira T, de Azevedo M, Diniz Luerce T, Mariadassou M, Longaray Delamare AP, Langella P, Maguin E, Azevedo V, Caetano de Faria AM, Miyoshi A, van de Guchte M.

PLoS One. 2014 Jan 21;9(1):e85923. doi: 10.1371/journal.pone.0085923. eCollection 2014.

8.

Th17 cells in immunity and autoimmunity.

Bedoya SK, Lam B, Lau K, Larkin J 3rd.

Clin Dev Immunol. 2013;2013:986789. doi: 10.1155/2013/986789. Epub 2013 Dec 26. Review.

9.

Interleukin-18 and IL-18 binding protein.

Dinarello CA, Novick D, Kim S, Kaplanski G.

Front Immunol. 2013 Oct 8;4:289. doi: 10.3389/fimmu.2013.00289. Review.

10.

Microbiota regulation of inflammatory bowel disease and colorectal cancer.

Liu Z, Cao AT, Cong Y.

Semin Cancer Biol. 2013 Dec;23(6 Pt B):543-52. doi: 10.1016/j.semcancer.2013.09.002. Epub 2013 Sep 23. Review.

11.

Polymer-conjugated inhibitors of tumor necrosis factor-α for local control of inflammation.

Washburn NR, Prata JE, Friedrich EE, Ramadan MH, Elder AN, Sun LT.

Biomatter. 2013 Jul-Sep;3(3). pii: e25597. doi: 10.4161/biom.25597. Epub 2013 Jul 10. Review.

12.

Identification of canonical tyrosine-dependent and non-canonical tyrosine-independent STAT3 activation sites in the intracellular domain of the interleukin 23 receptor.

Floss DM, Mrotzek S, Klöcker T, Schröder J, Grötzinger J, Rose-John S, Scheller J.

J Biol Chem. 2013 Jul 5;288(27):19386-400. doi: 10.1074/jbc.M112.432153. Epub 2013 May 14.

13.

The impact of JNK inhibitor D-JNKI-1 in a murine model of chronic colitis induced by dextran sulfate sodium.

Kersting S, Behrendt V, Kersting J, Reinecke K, Hilgert C, Stricker I, Herdegen T, Janot MS, Uhl W, Chromik AM.

J Inflamm Res. 2013 May 3;6:71-81. doi: 10.2147/JIR.S40092. Print 2013.

14.

Linking vitamin d deficiency to inflammatory bowel disease.

Palmer MT, Weaver CT.

Inflamm Bowel Dis. 2013 Sep;19(10):2245-56. doi: 10.1097/MIB.0b013e31828a3b6f. Review.

15.

Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.

Guo Y, Lu N, Bai A.

Biomed Res Int. 2013;2013:581631. doi: 10.1155/2013/581631. Epub 2013 Jan 21. Review.

16.

The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin.

Weaver CT, Elson CO, Fouser LA, Kolls JK.

Annu Rev Pathol. 2013 Jan 24;8:477-512. doi: 10.1146/annurev-pathol-011110-130318. Epub 2012 Nov 15. Review.

17.

The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells.

Powell N, Walker AW, Stolarczyk E, Canavan JB, Gökmen MR, Marks E, Jackson I, Hashim A, Curtis MA, Jenner RG, Howard JK, Parkhill J, MacDonald TT, Lord GM.

Immunity. 2012 Oct 19;37(4):674-84. doi: 10.1016/j.immuni.2012.09.008. Epub 2012 Oct 11.

18.

Host-microbiota interactions in inflammatory bowel disease.

Elson CO, Cong Y.

Gut Microbes. 2012 Jul-Aug;3(4):332-44. Epub 2012 May 10. Review.

19.

Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease.

Lindebo Holm T, Poulsen SS, Markholst H, Reedtz-Runge S.

Int J Inflam. 2012;2012:412178. doi: 10.1155/2012/412178. Epub 2012 Feb 19.

20.

Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci.

Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, Debrus S, Raelson JV, Tejasvi T, Belouchi M, West SL, Barker JN, Kõks S, Kingo K, Balschun T, Palmieri O, Annese V, Gieger C, Wichmann HE, Kabesch M, Trembath RC, Mathew CG, Abecasis GR, Weidinger S, Nikolaus S, Schreiber S, Elder JT, Weichenthal M, Nothnagel M, Franke A.

Am J Hum Genet. 2012 Apr 6;90(4):636-47. doi: 10.1016/j.ajhg.2012.02.020.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk